Innovative Growth for BrainsWay in Q2 2025
BrainsWay Ltd. (NASDAQ: BWAY), a pioneering company in neurostimulation treatments, recently showcased remarkable performance for the second quarter of 2025. The company reported a record revenue of $12.6 million, marking a substantial 26% increase compared to the same period last year.
Financial Highlights
During Q2 2025, BrainsWay not only achieved impressive revenue growth but also reported an operating profit of $0.6 million. Adjusted EBITDA rose 16% to reach $1.5 million compared to $1.3 million from Q2 2024, demonstrating enhanced operational efficiency. Additionally, the net profit surged to $2 million, reflecting a staggering 233% increase year-over-year.
Revenue Surge and Strategic Agreements
As the company capitalizes on its robust business model, approximately 70% of recent customer engagements are structured as multi-year lease agreements. This strategy has resulted in a substantial $62 million in remaining performance obligations from customers under signed multi-year contracts.
Product Implementation and Market Expansion
BrainsWay has successfully shipped 88 of its Deep TMS™ systems in Q2 2025, representing a 35% increase from Q2 2024. The installed base now totals 1,522 systems, reinforcing the company's market position. The gross margin held steady at 75%, while the company also maintained the same operating income as the prior year.
Guidance and Market Outlook
Reflecting on its current performance, BrainsWay adjusted its full-year 2025 revenue guidance to between $50 million and $52 million, alongside an adjusted EBITDA target of 12% to 13%. Previously, revenue expectations were set between $49 million and $51 million.
CEO Reflections on Progress
Hadar Levy, CEO of BrainsWay, expressed optimism regarding the company’s trajectory. He stated, "The second quarter results exhibit our momentum in the market and the successful execution of our growth strategy. The recurring revenue streams through multi-year agreements have proven to strengthen our fiscal position, and we look forward to expanding our reach and impact in mental health care."
Strategic Initiatives and Future Plans
BrainsWay has commenced an equity financing transaction with Stella MSO, LLC, a management organization that supports multiple mental health clinics across the U.S. and Israel, which have provided services to over 30,000 patients. This partnership signifies an exciting avenue for rapid growth and increased awareness of BrainsWay's transformative Deep TMS technology.
Preparation for Upcoming Webcast
To further engage with stakeholders and investors, BrainsWay's management will hold a conference call to discuss these results and field any inquiries. The call is scheduled for 8:30 AM Eastern Time.
Company Overview
Founded in 2003, BrainsWay is committed to advancing the field of neuroscience with its innovative Deep Transcranial Magnetic Stimulation (Deep TMS™). The company is the first TMS provider to gain multiple FDA-clearances for its technology, which has been validated through comprehensive clinical studies. Current applications include treating major depressive disorder, obsessive-compulsive disorder, and smoking addictions, with ongoing trials investigating additional psychiatric and neurological disorders.
Frequently Asked Questions
What is BrainsWay's recent revenue achievement?
BrainsWay reported a record revenue of $12.6 million for Q2 2025, reflecting a 26% increase year-over-year.
How has BrainsWay's profit changed?
The company's net profit for Q2 2025 increased to $2 million, a rise of 233% over the previous year's second quarter.
What future revenue guidance has BrainsWay provided?
BrainsWay raised its revenue guidance for 2025 to between $50 million and $52 million, with an adjusted EBITDA target set at 12% to 13%.
What is Deep TMS technology?
Deep TMS is a noninvasive neurostimulation technology used to treat various mental health disorders, including depression and OCD.
When is the next conference call for BrainsWay?
The conference call to discuss Q2 results will be held at 8:30 AM Eastern Time on the scheduled date.
